SSY Group Wins China Approval for Bicarbonate Peritoneal Dialysis SolutionPUBT·Nov 13, 2026 at 04:02 AM02005-0.58%
SSY Group Nine-Month Profit Attributable to Shareholders Rises 15.5% to HK$ 460 MillionPUBT·Oct 26, 2026 at 08:32 AM02005-0.58%
SSY Group Wins China Bulk Drug Approval for Labetalol, Strengthening Hypertension PortfolioTip Ranks·Oct 22, 2026 at 04:07 AM02005-0.58%
SSY Group Wins China Approval for Nimodipine Oral Solution, Expands Neurology PortfolioTip Ranks·Oct 8, 2026 at 09:11 AM02005-0.58%
SSY Group (SEHK:2005) Looks Fairly Valued After Boardroom ChangeSimplywall·Oct 7, 2026 at 11:09 AM02005-0.58%
SSY Group Revamps Board as Veteran Executive Wu Hengyao Joins, Su Xuejun Steps DownTip Ranks·Sep 28, 2026 at 11:38 AM02005-0.58%
SSY Group Sets Out Board Composition and Committee RolesTip Ranks·Sep 28, 2026 at 11:38 AM02005-0.58%
SSY Group (SEHK:2005) Faces A Valuation Test Following Two China Drug ApprovalsSimplywall·Sep 23, 2026 at 02:07 AM02005-0.58%
SSY Group Wins China Approval for New Letermovir InjectionTip Ranks·Sep 10, 2026 at 04:07 AM02005-0.58%